Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million

Rhea-AI Summary

Meihua International Medical Technologies (MHUA) announced a $3 million share repurchase program approved by its board. The program allows MHUA to buy back outstanding ordinary shares through open market or private transactions, complying with securities laws and the company's insider trading policy. CEO Xin 'Steven' Wang highlighted that the repurchase reflects confidence in the company's future and commitment to enhancing shareholder value. The repurchased shares will be cancelled. The program can be suspended or discontinued anytime and will begin after the semi-annual report's filing for the period ending June 30, 2024.

Positive

• Share Repurchase Program of up to $3 million announced.
• Repurchased shares will be cancelled, reducing outstanding shares and potentially increasing EPS.
• Reflects company confidence in future growth and commitment to enhancing shareholder value.

Negative

• The program does not obligate the company to repurchase any specific amount of shares.
• The buyback can be suspended or discontinued at any time.

Financial Analyst

Share repurchase programs often indicate that a company believes its stock is undervalued. By buying back up to $3 million worth of its own shares, Meihua International Medical Technologies is likely signaling its confidence in future financial performance. This move can benefit shareholders in several ways: it may boost the stock price due to reduced shares in circulation, potentially lead to higher earnings per share (EPS) and demonstrate the company's efficient cash management.

However, investors should consider the scale of the repurchase. $3 million is not a large amount for many companies, especially in the healthcare sector. The financial impact might be limited if the company's market cap is significant. Additionally, share repurchases can sometimes signal the company lacks better investment opportunities to generate higher returns.

Market Research Analyst

From a market perspective, the share repurchase program could enhance Meihua's stock attractiveness. The decision to buy back shares during a period of innovation and expansion suggests a stable financial footing. The company's mention of innovations and operational efficiencies introduced through AI also highlights a forward-thinking approach that could attract tech-savvy investors.

However, caution is warranted. Market conditions and other external factors can affect the actual execution of the share repurchase. The program's success also depends on the company's continued ability to generate significant cash flow. Investors should closely monitor upcoming financial reports for more detailed insights into the company's performance and cash reserves.

YANGZHOU, China, July 1, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced today that its board of directors (the "Board") has approved and authorized a share repurchase program of up to $3 million of the Company's outstanding ordinary shares (the "Share Repurchase Program"). The Company intends to cancel all shares repurchased pursuant to this Share Repurchase Program.

The ordinary shares may be repurchased from time to time through open market purchases or privately negotiated transactions at prevailing prices, in accordance with securities laws and other legal requirements, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company's insider trading policy, and subject to market conditions and other factors.

"With ongoing efforts to innovate, expand our premium product offerings, and enhance operational efficiency through optimized production processes and the application of AI, we continue to strengthen our business model and generate significant cash flow, which enables us to invest for the long term," said Xin "Steven" Wang, Chief Executive Officer of Meihua. "This Share Repurchase Program including the planned cancellation of repurchased shares not only underscores our confidence in Meihua's future growth but also demonstrates our commitment to enhancing shareholder value through concrete actions."

The adoption of this Share Repurchase Program does not obligate the Company to acquire any specific amount of ordinary shares, and it may be suspended or discontinued at any time by the Board.

The Company expects to implement the Share Repurchase Program and a corresponding 10b5-1 plan following the filing of its Semi-Annual Report on Form 6-K for the period ending June 30, 2024.

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua's own brands and are also sourced and distributed from other manufacturers. The Company has received an international "CE" certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

For more information, please visit www.meihuamed.com.

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company's future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, including under the section entitled "Risk Factors" in its annual report on Form 20-F, as well as on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

IR Department
Email: secretary@meihuamed.com
Tel: +86-0514-89800199

Christensen
Yang Song
Email: yang.song@christensencomms.com
Tel: +86-010-59001548

View original content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-co-ltd-announces-share-repurchase-program-of-up-to-3-million-302186765.html

SOURCE Meihua International Medical Technologies Co., Ltd.

FAQ

What is the share repurchase program announced by Meihua International Medical Technologies?

Meihua International Medical Technologies announced a $3 million share repurchase program to buy back outstanding ordinary shares and cancel them.

When will Meihua International Medical Technologies implement its share repurchase program?

The share repurchase program will start after the filing of the semi-annual report for the period ending June 30, 2024.

How will the share repurchase program affect Meihua International Medical Technologies' shares?

The repurchased shares will be cancelled, potentially increasing earnings per share (EPS) and enhancing shareholder value.

Can Meihua International Medical Technologies suspend the share repurchase program?

Yes, the board can suspend or discontinue the share repurchase program at any time.